Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
The Journal of Dermatological Treatment|October 10, 2024
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis)Luigi Gargiulo, Luciano Ibba, Angela Alfano, et al.
Frontiers in Medicine|August 24, 2023
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, et al.
Dermatology and Therapy|May 29, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)Luca Potestio, Cataldo Patruno, Silvia Mariel Ferrucci, et al.
The Journal of Dermatological Treatment|May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Dermatology and Therapy|April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Clinical and Experimental Dermatology|July 15, 2025
Therapeutic Outcomes Across JAK Inhibitors in Prurigo NodularisGianluca Avallone, Andrea Bombelli, Luca Valtellini, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 29, 2024
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort studyGianluca Avallone, Francesco Cavallo, Annalisa Tancredi, et al.
Dermatology Practical & Conceptual|February 28, 2024
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Dermatology and Therapy|October 10, 2025
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort StudyGianluca Avallone, Andrea Bombelli, Luigi Gargiulo, et al.
Clinical and Experimental Dermatology|July 9, 2026
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter StudyMaddalena Napolitano, Giuseppe Lauletta, Marianna Cimmino, et al.
Pageof 8